Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

[Combination drug therapy in patients with BPH].

Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA.

Urologiia. 2018 Mar;(1):101-105. Russian.

PMID:
29634142
2.

A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.

Alter A, Chaisson N, Mukherjee S, Gildea T.

Chest. 2018 Feb;153(2):e33-e36. doi: 10.1016/j.chest.2017.08.021.

PMID:
29406237
3.

Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.

Duan Y, Grady JJ, Albertsen PC, Helen Wu Z.

Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):340-348. doi: 10.1002/pds.4361. Epub 2018 Jan 9.

PMID:
29316005
4.

A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, Karanastasis D, Plastino J, Giuliano F, Rosen RC.

BJU Int. 2018 Apr;121(4):647-658. doi: 10.1111/bju.14057. Epub 2017 Nov 16.

PMID:
29044968
5.

[Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].

Vinarov AZ, Spivak LG, Mironov AV.

Urologiia. 2017 Sep;(4):120-128. Russian.

PMID:
28952704
6.

Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.

Burns O, Zhu J, Manyak MJ, Ravindranath R, Koosha F, Haque N, Chung S.

Clin Pharmacol Drug Dev. 2018 May;7(4):422-434. doi: 10.1002/cpdd.380. Epub 2017 Aug 11.

PMID:
28800206
7.

Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.

Traish A, Haider KS, Doros G, Haider A.

Horm Mol Biol Clin Investig. 2017 Jun 21;30(3). pii: /j/hmbci.2017.30.issue-3/hmbci-2017-0015/hmbci-2017-0015.xml. doi: 10.1515/hmbci-2017-0015.

PMID:
28632494
9.

Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.

De Nunzio C, Brassetti A, Proietti F, Gacci M, Serni S, Esperto F, Tubaro A.

Neurourol Urodyn. 2017 Nov;36(8):2096-2100. doi: 10.1002/nau.23247. Epub 2017 Mar 3.

PMID:
28257560
10.

Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation.

Kurczewski R, Bowen C, Collins D, Zhu J, Serbest G, Manyak M.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):508-516. doi: 10.1002/cpdd.334. Epub 2017 Jan 27.

PMID:
28127948
11.

[Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].

Höfner K, Ulrich S, Berges R.

Urologe A. 2017 May;56(5):645-653. doi: 10.1007/s00120-016-0296-x. Review. German.

PMID:
27981373
12.

Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review.

Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D.

Biomed Pharmacother. 2016 Oct;83:1141-1145. doi: 10.1016/j.biopha.2016.08.021. Epub 2016 Aug 20. Review.

PMID:
27551761
13.

Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, Puzzolo D, Valenti A, Pisani A, Adamo EB, Altavilla D, Squadrito F, Micali A.

Int J Mol Sci. 2016 Aug 11;17(8). pii: E1311. doi: 10.3390/ijms17081311. Review.

15.

Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

Fossler M, Zhu J, Roehrborn C, McAleese P, Manyak M.

Clin Drug Investig. 2016 Sep;36(9):763-767. doi: 10.1007/s40261-016-0419-6.

PMID:
27356530
16.

Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.

Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Palacios JM, Vasylyev A, Manyak MJ.

World J Urol. 2017 Mar;35(3):421-427. doi: 10.1007/s00345-016-1884-5. Epub 2016 Jun 22.

17.

Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers.

Li H, Yang J, Zhao H, Fossler MJ, Wang C.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):427-33. doi: 10.1002/cpdd.197. Epub 2015 Jul 20.

PMID:
27137714
18.

Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.

Dimitropoulos K, Gravas S.

Ther Adv Urol. 2016 Feb;8(1):19-28. doi: 10.1177/1756287215607419. Review.

19.
20.

Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.

Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, García-Rojo D, Brenes-Bermúdez FJ, Cózar-Olmo JM, Baena-González V, Manasanch J.

Int Urol Nephrol. 2016 May;48(5):645-56. doi: 10.1007/s11255-015-1206-7. Epub 2016 Jan 25.

Supplemental Content

Loading ...
Support Center